Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 11 Commerce Dr Fl 1 CRANFORD NJ 07016-3501 |
Tel: | 1-908-9676677 |
Website: | https://www.citiuspharma.com |
IR: | See website |
Key People | ||
Leonard L. Mazur Executive Chairman of the Board, Chief Executive Officer, Company Secretary | Myron Z. Holubiak Executive Vice Chairman of the Board | Jaime Bartushak Chief Financial Officer, Chief Business Officer |
Myron S. Czuczman Chief Medical Officer, Executive Vice President | Ilanit Allen Vice President - Corporate Communications and Investor Relations |
Business Overview |
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Halo-Lido is a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. NoveCite is a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. |
Financial Overview |
For the three months ended 31 December 2023, Citius Pharmaceuticals Inc revenues was not reported. Net loss increased from $3.6M to $9.2M. Higher net loss reflects Gain on sale of New Jersey net operating decrease from $3.6M (income) to $0K, Stock-based Compensation in SGA increase from $1.2M to $3.1M (expense), General and administrative increase of 41% to $3.7M (expense). |
Employees: | 22 as of Sep 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $93.65M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$38.82M as of Dec 31, 2023 |
Net annual income (TTM): | -$39.33M as of Dec 31, 2023 |
Free cash flow (TTM): | -$30.37M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 159,094,781 as of Feb 10, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |